Injectable GLP-1s work but the problem is everything else about them. The weekly needle, the cold storage, the clinical setting. Oral alternatives exist but efficacy remains the ceiling. Lionbio is working inside of this gap.

We developed a patented intranasal delivery platform for GLP-1 therapeutics that matches injectable efficacy without the injection. And unlike most biotech companies, we own the entire arc from preclinical formulation and manufacturing to the product that lands in a patient's home. No hand-off to a distribution brand or dilution through a telehealth middleman. We control the science, the quality, and the consumer experience.

Our scientific leadership includes pioneers in nanoparticle delivery, vascular tissue engineering, and human organoid disease modeling, with deep roots in preclinical development and biomedical research at Columbia University.

We're looking for researchers, translational scientists, and operators who want to be part of that full journey from the lab to the patient's home. If you care about what the product actually is when it reaches someone's hands, and want ownership over the manufacturing quality and patient experience that makes it real, join us.

hello@lion.bio